Forskning
Udskriv Udskriv
Switch language
Region Hovedstaden - en del af Københavns Universitetshospital
Udgivet

Efficacy of Ion-Channel Inhibitors Amantadine, Memantine and Rimantadine for the Treatment of SARS-CoV-2 In Vitro

Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

DOI

  1. Focal Epithelial Hyperplasia

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. The Effect of Prophylactic HPV Vaccines on Oral and Oropharyngeal HPV Infection-A Systematic Review

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  3. A Contemporary Systematic Review on Repartition of HPV-Positivity in Oropharyngeal Cancer Worldwide

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  1. Inferior cure rate in pilot study of 4-week glecaprevir/pibrentasvir treatment with or without ribavirin of chronic hepatitis C

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  2. Viral genome wide association study identifies novel hepatitis C virus polymorphisms associated with sofosbuvir treatment failure

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

  3. Hepatitis C virus envelope protein dynamics and the link to hypervariable region 1

    Publikation: Bidrag til tidsskriftReviewForskningpeer review

  4. Neutralisation titres against SARS-CoV-2 are sustained 6 months after onset of symptoms in individuals with mild COVID-19

    Publikation: Bidrag til tidsskriftTidsskriftartikelForskningpeer review

Vis graf over relationer

We report the in vitro efficacy of ion-channel inhibitors amantadine, memantine and rimantadine against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2). In VeroE6 cells, rimantadine was most potent followed by memantine and amantadine (50% effective concentrations: 36, 80 and 116 µM, respectively). Rimantadine also showed the highest selectivity index, followed by amantadine and memantine (17.3, 12.2 and 7.6, respectively). Similar results were observed in human hepatoma Huh7.5 and lung carcinoma A549-hACE2 cells. Inhibitors interacted in a similar antagonistic manner with remdesivir and had a similar barrier to viral escape. Rimantadine acted mainly at the viral post-entry level and partially at the viral entry level. Based on these results, rimantadine showed the most promise for treatment of SARS-CoV-2.

OriginalsprogEngelsk
Artikelnummer2082
TidsskriftViruses
Vol/bind13
Udgave nummer10
ISSN1999-4915
DOI
StatusUdgivet - 15 okt. 2021

ID: 68561622